Alnylam Pharmaceuticals

Latest news

• Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% (opens in a new tab)

  Simply Wall Street · Oct 2, 2026

• Alnylam Pharmaceuticals, Carvana, MongoDB (opens in a new tab)

  TradingView · Sep 30, 2026

• Alnylam drafts football veteran Pete Shaw for heart disease education push (opens in a new tab)

  Fierce Pharma · Sep 30, 2026

• Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside (opens in a new tab)

  NAI500 · Sep 29, 2026

• Alnylam shares drop 18% after AstraZeneca/Ionis trial failure, but outlook remains cautiously optimistic. (opens in a new tab)

  Pluang · Sep 28, 2026

• Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) (opens in a new tab)

  Seeking Alpha · Sep 28, 2026

• 18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. (opens in a new tab)

  The Motley Fool · Sep 28, 2026

• Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com (opens in a new tab)

  Investing.com Nigeria · Sep 27, 2026

• Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) (opens in a new tab)

  Seeking Alpha · Sep 26, 2026

• The next Alnylam? RNAi biotech City Therapeutics files for IPO (opens in a new tab)

  Endpoints News · Sep 25, 2026

• Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Sep 2026 $ALNY (opens in a new tab)

  MarketBeat · Sep 24, 2026

• H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455 (opens in a new tab)

  Moomoo · Sep 21, 2026

• Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook (opens in a new tab)

  Yahoo Finance · Sep 20, 2026

• Will RNAi Market Growth Change Alnylam Stock's Narrative? (opens in a new tab)

  Simply Wall Street · Sep 20, 2026

• Alnylam Pharmaceuticals (ALNY) Highlighted As An Oligonucleotide Therapeutics Leader Through 2035 (opens in a new tab)

  Simply Wall Street · Sep 17, 2026

• Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture (opens in a new tab)

  The Motley Fool · Sep 15, 2026

• Alnylam at Morgan Stanley conference: ttr growth offsets guidance trim (opens in a new tab)

  Investing.com · Sep 14, 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Gap Fill Strategy (opens in a new tab)

  dars.gov.et · Sep 10, 2026

• Here’s Why Alnylam Pharmaceuticals (ALNY) Declined (opens in a new tab)

  Yahoo Finance · Sep 10, 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Safe Entry Stocks (opens in a new tab)

  dars.gov.et · Sep 10, 2026

• Why Alnylam Pharmaceuticals (ALNY) Stock Is Down Today (opens in a new tab)

  Quiver Quantitative · Sep 10, 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Moving Average Crossovers (opens in a new tab)

  dars.gov.et · Sep 10, 2026